What are the effects of levothyroxine on athletic performance in hypothyroid versus euthyroid athletes?

Levothyroxine and Athletic Performance

Direct Answer: Levothyroxine Does Not Enhance Performance in Euthyroid Athletes and Provides Only Modest Benefits in Hypothyroid Athletes

In euthyroid (normal thyroid function) athletes, levothyroxine provides no performance advantage and carries significant health risks including atrial fibrillation, bone loss, and cardiovascular complications. 1 In athletes with true hypothyroidism, levothyroxine restores normal physiological function but does not enhance performance beyond baseline euthyroid capacity. 2, 3

---

Performance Effects in Hypothyroid Athletes

Cardiovascular Improvements (Most Consistent Finding)

Levothyroxine therapy in subclinical hypothyroidism reverses specific cardiac abnormalities that impair exercise capacity:

• Diastolic dysfunction is corrected, improving cardiac filling and stroke volume during exercise 2
• Systemic vascular resistance decreases, reducing cardiac afterload and improving cardiac output 2
• Cardiopulmonary reserve increases, with measurable improvements in oxygen uptake (VO₂) and minute ventilation at submaximal exercise intensities 4
• Heart rate response normalizes, with treated patients achieving lower heart rates at equivalent workloads compared to their untreated state 4

In one controlled trial, subclinical hypothyroid patients showed significant improvement after 6 months of TSH normalization: oxygen uptake decreased from 24.1±6.3 to 17.1±4.2 ml·kg·min⁻¹ (p=0.03), minute ventilation improved from 28.0±8.1 to 23.5±5.6 L·min⁻¹ (p=0.03), and heart rate decreased from 128±17 to 121±17 bpm (p=0.03). 4

Musculoskeletal Improvements

Levothyroxine produces measurable strength and mobility gains in hypothyroid patients:

• Upper body strength increases significantly: chest press performance improved (p=0.002) and right-hand grip strength increased (p=0.009) after TSH normalization 5
• Lower body strength improves: leg extension strength showed significant gains (p<0.001) 5
• Mobility enhances: shoulder mobility (p<0.001) and hip mobility (p=0.07) improved with treatment 5
• Explosive power increases: significant improvement in explosive strength testing (p=0.041) 5
• Anaerobic threshold rises: a trend toward improved anaerobic threshold (p=0.13) was observed 5

Metabolic Effects (Limited and Inconsistent)

The metabolic benefits of levothyroxine in hypothyroid athletes are disappointing:

• Exercise tolerance remains impaired even after TSH normalization, with maximal power output (p=0.02) and VO₂max (p=0.04) remaining reduced compared to euthyroid controls 6
• Substrate utilization abnormalities persist: respiratory quotient increments remain significantly higher in treated hypothyroid patients versus controls (p<0.04), indicating continued reliance on carbohydrate metabolism 6
• Lactate accumulation is not corrected: blood lactate and pyruvate rise with steeper slopes during exercise (p<0.0001 and p<0.001) even after 6-12 months of euthyroid restoration 6
• Resting metabolic rate does not change: no significant alterations in energy expenditure or respiratory quotient were observed with levothyroxine treatment (p>0.05) 5
• Body composition remains unchanged: no improvements in muscle mass, fat mass, or body weight occur with levothyroxine therapy (p>0.05) 5

---

Critical Distinction: Hypothyroid vs. Euthyroid Athletes

In Hypothyroid Athletes

Levothyroxine is medically indicated and restores impaired physiological function:

• TSH >10 mIU/L warrants treatment regardless of symptoms due to ~5% annual risk of progression to overt hypothyroidism and associated cardiac dysfunction 1
• Symptomatic athletes with TSH 4.5-10 mIU/L may benefit from a 3-4 month therapeutic trial, particularly if anti-TPO antibody positive (4.3% vs 2.6% annual progression risk) 1
• Treatment goals are restoration of normal function, not performance enhancement beyond euthyroid baseline 2, 3

In Euthyroid Athletes

Levothyroxine use is inappropriate and dangerous:

• No scientific evidence supports performance enhancement in athletes with normal thyroid function 3
• Approximately 25% of patients on levothyroxine become overtreated with TSH suppression <0.1 mIU/L, increasing atrial fibrillation risk 3-5 fold, osteoporosis, fractures, and cardiovascular mortality 1
• The World Anti-Doping Agency has not banned thyroid medication because current evidence does not demonstrate ergogenic potential 3

---

Diagnostic Considerations in Athletes

Overlapping Symptoms Create Diagnostic Challenges

Hypothyroidism symptoms (fatigue, depression, impaired sleep, muscle stiffness) mirror overtraining syndrome, potentially leading to inappropriate thyroid testing and treatment:

• Standard screening (TSH and free T4) may miss early hypothyroidism in athletes with hypothalamic-pituitary dysfunction from overtraining 3
• TRH stimulation testing is advocated by some experts for detecting earliest stages of hypothyroidism, though not universally recommended 3
• No association has been identified between training state and hypothyroidism in current research 3

Appropriate Testing Algorithm

When hypothyroidism is suspected in an athlete:

1. Measure TSH and free T4 as initial screening (sensitivity ~98%, specificity ~92%) 1
2. Repeat testing in 3-6 weeks if abnormal, as 30-60% of elevated TSH values normalize spontaneously 1
3. Measure anti-TPO antibodies to identify autoimmune etiology and predict progression risk 1
4. Consider TRH stimulation testing only in athletes with persistent symptoms despite normal basal thyroid tests and suspected hypothalamic-pituitary dysfunction 3

---

Treatment Principles for Hypothyroid Athletes

Initiation and Dosing

• Start levothyroxine at 1.6 mcg/kg/day in athletes <70 years without cardiac disease for rapid TSH normalization 1
• Use lower starting doses (25-50 mcg/day) in athletes with cardiac disease or >70 years, titrating by 12.5-25 mcg every 6-8 weeks 1
• Target TSH 0.5-4.5 mIU/L with normal free T4 to avoid both under- and overtreatment 1

Monitoring

• Recheck TSH and free T4 every 6-8 weeks during dose titration until target range achieved 1
• Monitor TSH every 6-12 months once stable, or sooner if symptoms change 1
• Free T4 helps interpret ongoing abnormal TSH during therapy, as TSH may lag behind T4 normalization 1

Safety Precautions

• Screen for adrenal insufficiency before initiating levothyroxine (morning cortisol and ACTH), as thyroid hormone can precipitate adrenal crisis in undiagnosed patients 1, 7
• Avoid TSH suppression <0.1 mIU/L, which dramatically increases atrial fibrillation risk (3-5 fold), bone loss, and cardiovascular mortality 1
• Reduce dose by 25-50 mcg immediately if TSH falls <0.1 mIU/L, or by 12.5-25 mcg if TSH 0.1-0.45 mIU/L 1

---

Common Pitfalls in Athletic Populations

Inappropriate Levothyroxine Use

• Do not treat based on a single elevated TSH value without confirmation, as transient elevations are common 1
• Do not prescribe levothyroxine for weight management, fatigue, or depression in euthyroid athletes, as high-certainty evidence shows no benefit in quality of life or symptom improvement 8
• Recognize that overtreatment occurs in 14-21% of treated patients, with serious cardiovascular and skeletal consequences 1

Misdiagnosis of Overtraining as Hypothyroidism

• Overtraining syndrome shares symptoms with hypothyroidism (fatigue, depression, impaired sleep), but requires different management 3
• Hypothalamic-pituitary dysfunction in overtrained athletes may complicate thyroid test interpretation, potentially leading to false-negative results with standard TSH/free T4 screening 3

Drug Interactions Affecting Athletes

Several medications and supplements commonly used by athletes can interfere with levothyroxine:

• Iron, calcium supplements, and antacids reduce levothyroxine absorption when taken within 4 hours; separate administration by at least 4 hours 9
• Soybean flour, cottonseed meal, walnuts, and dietary fiber bind levothyroxine in the gastrointestinal tract, decreasing absorption 9
• Sympathomimetics (common in pre-workout supplements) combined with levothyroxine may increase coronary insufficiency risk in athletes with underlying cardiac disease 9

---

Evidence Quality and Limitations

Strength of Current Evidence

• Cardiovascular improvements with levothyroxine in subclinical hypothyroidism are supported by fair-quality evidence from controlled trials showing consistent cardiac benefits 2, 4
• Musculoskeletal improvements are documented in fair-quality studies with objective strength and mobility measurements 5
• Metabolic effects remain poorly understood, with conflicting data on exercise tolerance and substrate utilization even after prolonged euthyroid restoration 6
• No athlete-specific performance data exist to guide treatment decisions beyond standard clinical criteria 2, 3

Research Gaps

• No studies have evaluated levothyroxine's effects on competitive athletic performance in properly designed trials 3
• The relationship between training state and thyroid function requires further investigation to determine if intense training induces hypothyroidism 3
• Provocative testing (TRH stimulation) needs validation in athletic populations with suspected hypothalamic-pituitary dysfunction 3

---

Bottom Line for Clinical Practice

Levothyroxine should be prescribed to athletes only when clear diagnostic criteria for hypothyroidism are met (TSH >10 mIU/L, or TSH 4.5-10 mIU/L with symptoms/positive antibodies), not for anticipated performance gains. 1, 2 Treatment restores impaired physiological function in hypothyroid athletes but does not enhance performance beyond euthyroid baseline. 2, 3 In euthyroid athletes, levothyroxine provides no benefit and carries substantial cardiovascular and skeletal risks from overtreatment. 1, 8 Until robust athlete-specific data emerge, treatment decisions must follow established clinical guidelines prioritizing patient safety over unproven ergogenic potential. 2, 3